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AbstrACt
Introduction Patients presenting to emergency 
departments (EDs) with epistaxis uncontrolled by 
subsequent simple first aid measures or application of 
topical vasoconstrictors will typically undergo anterior 
nasal packing. Packing is effective, but can be extremely 
painful and unpleasant and patients usually need hospital 
admission. Tranexamic acid (TXA) is a cheap, safe, readily 
available antifibrinolytic agent known to be beneficial in 
a variety of clinical settings where uncontrolled bleeding 
may be a problem. Anecdotal evidence suggests that 
topical TXA may be of value in persistent epistaxis; 
however, further evaluation is required.
Methods and analysis This is a multicentre, double-
blind, parallel group, randomised, controlled trial 
comparing the use of topical intranasal TXA with 
indistinguishable placebo in adults presenting to UK 
EDs with persistent atraumatic epistaxis. Follow-up is 
at 1 week by structured telephone review. The primary 
outcome measure is the subsequent need for anterior 
nasal packing in the ED. Key secondary outcomes include 
the need for hospital admission, blood transfusion and/
or further treatment for epistaxis during the index ED 
attendance. Recruiting 450 patients will provide 90% 
power to demonstrate an absolute reduction in packing 
rate from 95% to 85%. An improvement of this magnitude 
would be of significant benefit to patients and healthcare 
providers and justify a change to standard practice. Given 
the low cost of TXA and its short administration time, a full 
economic evaluation is not being undertaken.
Ethics and dissemination The study has been approved 
by the South West—Bristol Research Ethics Committee 
(reference 17/SW/0010). We aim to publish the findings in 
a high impact, international peer-reviewed journal. Results 
will also be shared with the Hereditary Haemorrhagic 
Telangiectasia foundation and telangiectasia UK for 
dissemination through appropriate related forums.
trial registration number ISRCTN34153772 and 
EudraCT No: 2016-001530-10.
IntroduCtIon 
Epistaxis (nosebleed) is an extremely 
common condition which causes 60% of the 
population to seek medical attention at some 
point in their lives.1 Patients are frequently 
elderly, with the mean age of over 70 years.2 
In most cases, epistaxis resolves with simple 
measures. These may include firm pres-
sure with the thumb and index finger to 
the soft anterior part of the nose, the use 
of ice packs on the bridge of the nose and 
adopting a forward leaning posture. Many 
cases, however, are more serious, leading 
to hospital admission or even, occasionally, 
death.3 Current approaches to managing 
this condition in the emergency department 
(ED) beyond simple first aid include the use 
of topical vasoconstrictors, which have been 
shown to arrest bleeding in up to 65% of 
patients.4 Chemical cautery with silver nitrate 
may also be used but with profuse bleeds, it 
may be difficult to identify the bleeding site 
and successfully apply cautery.5 These initial 
measures may be partially successful and are 
occasionally repeated to stop the bleeding. 
If bleeding cannot be stopped with these 
measures, patients will usually undergo ante-
rior nasal packing.
While effective, nasal packing is recognised 
to be extremely uncomfortable for patients. 
The mean pain score associated with insertion 
strengths and limitations of this study
 ► Atraumatic epistaxis is a common presentation to 
the emergency department.
 ► This is a randomised, double-blind, placebo-con-
trolled study.
 ► The pragmatic study design ensures ease of recruit-
ment and minimal deviation from standard practice.
 ► Recruitment to emergency department research 
studies is notoriously difficult due to workload and 
staffing pressures.
 ► The wide variety of approaches to treatment in dif-
ferent centres and by different practitioners may lead 
to difficulties in standardisation of management.
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of the most commonly used nasal packs (the Merocel) 
has been shown to be higher than the average pain scores 
for patients with an acute myocardial infarction (heart 
attack).6 7 Nasal packs typically remain in situ for at least 
24 hours, which causes ongoing pain (reported mean pain 
scores 0.5–3.5/10) and an uncomfortable sensation of nasal 
obstruction. One typical published patient story reports, 
‘The packing had my face aching all night.’8 Removal is also 
painful with reported pain scores ranging from 0.4 to 7.4. In 
addition to the pain caused by this procedure, our unpub-
lished feasibility data demonstrate that 86% of patients who 
undergo anterior nasal packing are admitted to hospital 
and patients have a mean length of stay of 2 days. Nasal 
packing is also associated with a complication rate of up 
to 28%.9 Reported complications include infection, toxic 
shock syndrome, hypoxia, sleep apnoea, pack displacement 
with airway obstruction and bleeding on removal.
A recent unpublished national survey (Florey E, Reuben 
A, Appelboam A, 2014) has shown significant variation 
in the ED treatments used, which vary according to local 
protocols, clinician experience, available expertise and 
departmental workload. Feasibility data at three centres 
suggest that one-third of patients presenting to the ED 
with epistaxis subsequently require nasal packing.
Tranexamic acid (TXA) is an antifibrinolytic agent 
which acts by competitively binding to both plasmin-
ogen and plasmin in circulating blood at the site of 
injury, reducing the production and action of plasmin. 
Plasmin promotes the breakdown of fibrin, a protein that 
forms the stabilising framework of blood clots, therefore 
by inhibiting the action of plasmin, clots become more 
stable. TXA may be used via the intravenous or oral routes, 
having systemic action, or topically, where its effects are 
very localised, acting on the mucosa/blood vessels with 
which it is in contact.
TXA has been used in a variety of clinical and research 
settings with good evidence of its general efficacy and 
safety.10 A large randomised controlled trial (RCT) 
including 20 000 patients showed that intravenous TXA 
reduces mortality in patients with major trauma and 
suspected bleeding.11 Importantly, in this large trial, TXA 
did not cause an increase in thromboembolic compli-
cations. In a meta-analysis of 129 trials including 10 488 
patients, intravenous TXA was found to reduce mortality 
and the need for blood transfusion in patients under-
going surgery.12 No adverse events were noted in any of 
the patients receiving topical or intravenous treatment. 
When applied topically in patients undergoing surgery, 
TXA has been shown to reduce bleeding and the need 
for blood transfusion.10 The bioavailability of topical 
TXA is unknown (about 50% via gastrointestinal tract), 
but the systemic absorption of a topical dose of 200 mg 
(compared with the standard intravenous dose of 1 g) 
is extremely unlikely to result in significant side effects. 
Plasma concentrations following topical application are 
less than 1/10 of the level after intravenous administra-
tion.10 Results of an unpublished local study (Florey E, 
Appelboam A, Reuben A, 2015) to estimate the quantity 
of TXA absorbed through the nasal mucosa, suggested 
that of 200 mg applied to a dry dental roll, a maximum of 
39.8 mg is absorbed systemically, with an average of just 
14 mg. There are no absolute contraindications to the use 
of TXA and the large multicentre RCTs CRASH (Clin-
ical Randmoisation of an Antifibrinolytic in Significant 
Haemorrhage)11 and HALT-IT (Haemorrhage Allevia-
tion with tranexamic Acid - Initestinal System)13 have set 
a precedent with no notable exclusion criteria.
Topical application of TXA has the potential to inhibit 
local fibrinolysis at the site of bleeding with minimal 
systemic absorption.10 Our systematic review identified 
that two RCTs have evaluated topical TXA as a treatment 
for epistaxis.14 The first, conducted in 1995, randomised 
68 patients to receive topical TXA gel or placebo gel and 
demonstrated non-significant trends towards lower rates 
of continued bleeding after 30 min and rebleeding within 
30 days.15 However, the trial was underpowered to detect 
clinically important differences and significantly more 
patients who received TXA had presented with moderate 
or severe bleeds. The second trial randomised 216 patients 
to receive topical TXA (dental rolls soaked with 500 mg in 
5 mL of TXA) or anterior nasal packing. Significantly, fewer 
patients in the TXA group had active bleeding after 10 min 
with an absolute risk reduction of 40% (number needed to 
treat 2.5) suggesting substantial benefit. However, this trial 
was limited by a potential lack of allocation concealment 
and was unblinded.16 While they have limitations, these 
trials suggest that topical TXA is a promising treatment 
for epistaxis, which could reduce the need for patients to 
undergo a painful, unpleasant procedure (anterior nasal 
packing) with its attendant complications and hospital 
admissions. Topical TXA for persistent epistaxis may, there-
fore, be both beneficial for the patient (reduced nasal 
packing and reduced hospital admission) and for the 
healthcare system (saving on bed occupancy and providing 
a cheaper alternative to packing and admission).
AIMs And objECtIvEs
The aim of the study is to test the effectiveness of topical 
intranasal TXA in reducing the need for anterior nasal 
packing in adult patients presenting to the ED with spon-
taneous atraumatic epistaxis.
Key objectives are to compare the effect of topical TXA 
versus placebo on the need for anterior nasal packing, 
any further treatment in the ED, hospital admission and 
subsequent length of hospital stay, the requirement for 
blood products, the rebleeding rate for patients subse-
quently discharged from the ED and any adverse events, 
including thrombotic complications.
MEthods And AnAlysIs
study design
This study is a pragmatic 1:1 individually randomised, 
double-blind, parallel group placebo controlled multi-
centre trial. Four hundred and fifty patients presenting 
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to the ED with epistaxis and bleeding that persists after 
simple first aid measures, followed by standardised 
topical vasoconstrictor therapy will be randomised to 
receive either TXA or matched placebo (water for injec-
tion), soaked onto a cotton wool dental roll. Outcomes 
will include anterior nasal packing (primary), any further 
treatment for epistaxis during the index ED atten-
dance, hospital admission, length of stay, need for blood 
products and rebleeding rates for patients discharged 
home. Thrombotic complications will also be monitored 
as this is a recognised side effect of TXA, although this 
is considered a negligible risk with the low-dose topical 
TXA used in this study. Figure 1 illustrates the participant 
pathway through the trial.
A standard operating procedure (SOP) for the initial 
management of epistaxis has been implemented at 
Figure 1 Participant pathway. ED, emergency department; IMP, investigational medicinal product.
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participating sites prior to the study opening to recruit-
ment (online supplementary appendix 1). The purpose 
of this was to standardise (1) the application of digital 
pressure to compress the nose and (2) the use of a topical 
vasoconstrictor soaked on a cotton wool roll and gently 
inserted into the bleeding nostril. While not universally 
used, vasoconstrictor use has been shown to have utility in 
epistaxis and is advocated in national guidance.6 17 Partici-
pating sites are required to manage potential trial patients 
according to this standardised procedure for epistaxis 
management prior to confirming whether patients are 
eligible for inclusion in the trial. The current protocol is 
V.1.1, last updated on 2 September 2018.
study population and setting
The screening and recruitment of patients, delivery of the 
intervention and recording of outcomes will be carried 
out within participating UK National Health Service 
(NHS) EDs (online supplementary appendix 2).
screening, recruitment and consent
Adult patients (aged 18 or over) with acute spontaneous 
epistaxis and continued, uncontrolled bleeding after at 
least 10 min of simple first aid measures (eg, digital pres-
sure) will be screened for eligibility. Unstable patients or 
patients with an indication to proceed to immediate nasal 
packing will be excluded. Full inclusion and exclusion 
criteria for the trial are summarised in box 1.
Patients will be screened for eligibility by Good Clin-
ical Practice (GCP) trained staff. ED attendance logs will 
be screened for the duration of the trial to enable the 
identification of any missed patients and reporting of 
simple demographic data to ensure there is no evidence 
of recruitment bias.
Potentially eligible patients will give written informed 
consent (online supplementary file) during 10 min of 
treatment with a topical vasoconstrictor (eg, phenyleph-
rine or dilute epinephrine) soaked on a dental roll and 
standard nasal compression provided by a proprietary 
nasal clip, as directed by the SOP provided to partici-
pating sites. The written informed consent process will 
normally be undertaken by the attending clinician but 
may be delegated to another appropriate GCP-trained 
member of the research team depending on individual 
circumstances. Study team members nominated by the 
principal investigator to undertake the consent process 
will be listed as such on the study delegation log.
Potentially eligible patients will be provided with a 
concise participant information sheet (PIS), a verbal 
explanation of the purpose and nature of the trial 
and a description of what participation in the trial will 
entail. Patients will be given the opportunity to ask ques-
tions about the study. Patients providing consent and 
who continue to bleed after application of topical vaso-
constrictor are confirmed eligible and will proceed to 
randomisation. Informed consent will be sought prior 
to confirmation of eligibility in order to prevent delay to 
further treatment should the patient continue to bleed 
from their nose once the vasoconstrictor-soaked dental 
roll is removed.
Most bleeding can be at least temporarily controlled 
with nasal compression sufficient to allow written 
informed consent. However, witness consent will be 
permitted for patients who are unable to provide written 
consent, for example, due to continued active bleeding 
during nasal compression but who have full capacity and 
have expressed a clear interest in taking part. If a patient 
agrees to participate, he/she will be asked to complete an 
informed consent form which will be countersigned by 
the staff member taking consent. A record of the patient’s 
consent to participate will be documented in the hospital 
notes where a copy of the completed consent form and 
PIS will also be filed.
randomisation and blinding
Treatment allocations will be determined by randomisa-
tion stratified by centre using variable sized blocks, from 
a computer-generated allocation sequence provided by 
the clinical trials unit (CTU). Sequentially numbered 
tamper-evident trial packs will be supplied by the manu-
facturer containing a sealed phial of the trial solution, 
two dental rolls and study-specific labels for the trial docu-
mentation and patient’s notes. Patients will be allocated 
to receive TXA or placebo by selection of the next sequen-
tially numbered pack. Packs will be signed out by trained 
staff on the randomisation log. Appropriate sequential 
box 1 Inclusion and exclusion criteria
Inclusion criteria
Potential participants must satisfy the following criteria to be enrolled in 
the study:Potential participants must satisfy the following criteria to be 
enrolled in the study:
 ► Aged 18 or over.
 ► Presenting to the emergency department (ED) with spontaneous, 
atraumatic epistaxis, unresolved with simple first aid and standard 
initial therapy.
Exclusion criteria
Potential participants meeting any of the following criteria will be ex-
cluded from study participation:Potential participants meeting any of 
the following criteria will be excluded from study participation:
 ► Clinical evidence of shock, as determined by the treating clinician 
or requirement for resuscitation (including but not limited to systolic 
blood pressure <90 mm Hg).
 ► Known allergy to tranexamic acid.
 ► Lacking capacity to give consent.
 ► Unwilling to give consent.
 ► No telephone or unwilling to be contacted by telephone.
 ► Known nasopharyngeal, nasal cavity or paranasal malignancy.
 ► Pregnancy.
 ► Sent to ED for specialist ear, nose, throat treatment.
 ► Already undergone prehospital nasal packing.
 ► Prior participation in the study (ie, received allocated treatment).
 ► Prisoners.
 ► Epistaxis caused by trauma (excluding simple nose picking).
 ► Known haemophilia.
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use of packs will be strictly audited by the site research 
teams, trial manager and trial management group.
Consideration was given to the possible need for strat-
ification of patients according to anticoagulant use prior 
to randomisation. Local audit data from the Royal Devon 
and Exeter (RD&E) hospital have shown that packing 
rates for those on warfarin or one of the direct oral antico-
agulants, as compared with those who are not, are within 
5% of each other. Given the extra complexity that stratifi-
cation would introduce in a time-pressured environment, 
and the likelihood that randomisation will achieve a good 
balance, no such stratification has been included.
This is a double-blind study hence neither the research 
teams responsible for treating and assessing patients 
within this trial nor the participants themselves are aware 
of individual treatment allocations. Should the clinical 
need arise, a procedure is in place to enable emergency 
unblinding of treatment allocation.
trial interventions
Treatments in both arms of the trial are provided by 
Stockport Pharmaceuticals who are licensed to manu-
facture products for clinical trials under a Medicines 
and Healthcare products Regulatory Agency (MHRA) 
Manufacturers Authorisation (investigational medicinal 
product, IMP) licence. Participants will receive either:
Tranexamic acid: Presented in a phial containing 
4 mL of a 100 mg/mL solution, enough to saturate two 
standard cotton wool dental rolls. The standard prepara-
tion of TXA solution available in the UK contains 500 mg 
of drug in 5 mL of the clear, colourless solution. A cotton 
wool roll, such as is routinely used in the management 
of patients with epistaxis, will absorb approximately 2 mL 
(equivalent to 200 mg) of TXA.
Placebo: An identically presented phial containing 
4 mL of the excipient used for the active IMP, that is, 
water for injection.
Packaging for trial treatments will be identical. A flag 
label on the phial will be affixed to the trial-specific data 
collection form for drug accountability purposes. Trial 
drugs will be stored, at ambient temperature, in a secure 
drug cupboard within the ED accessible only to trained 
staff. Approximately 2 mL of solution will be used to satu-
rate a cotton wool dental roll which, once saturated, will 
be inserted into the patient’s nose. Sufficient solution 
will remain in the bottle to allow a second treatment 
according to the protocol.
The active and placebo solutions will be indistinguish-
able in appearance, taste and smell to patients and clini-
cians. All dental rolls will be left in situ for approximately 
10 min, timed by the research nurse or attending clini-
cian and accompanied by continued standardised nasal 
compression using a purpose designed disposable nasal 
clip. This is deemed to be a sufficient period for the forma-
tion and stabilisation of blood clots and hence control of 
bleeding. Patients, who deteriorate clinically during this 
period with uncontrolled bleeding or a fall in blood pres-
sure, or where urgent nasal packing is clinically indicated, 
will have their dental roll removed and receive further 
treatment as directed clinically. In our experience, this 
would be a very rare event if the patient was initially stable 
and eligible for the trial. Such patients will be included in 
the intention-to-treat analyses.
Participants with ongoing bleeding after 10 min treat-
ment with the IMP will undergo an identical second 
10 min treatment using the remaining allocated solution 
as long as they remain eligible and willing to continue in 
the study.
Participants, who are eligible and randomised but not 
treated with at least one dose of IMP, for example, because 
the bleeding stopped between randomisation and admin-
istration of IMP, will also be included in the intention-
to-treat analyses. However, participants randomised in 
error and in violation of the protocol, for example, when 
bleeding was not ongoing after vasoconstrictor therapy 
will be excluded.
Primary outcome measure
The primary outcome will be the use of anterior nasal 
packing (of any type) at any time during that ED atten-
dance. The need for packing will be determined after 
removal of the second trial dental roll by the treating 
clinician. Ongoing bleeding will be defined as the pres-
ence of visible blood below the nostril. Minor ongoing 
bleeding does not mandate nasal packing and the 
epistaxis management SOP will advise consideration of 
further measures such as silver nitrate cautery as appro-
priate. The decision to pack cannot be strictly defined 
and must be at the discretion of the clinician based on 
clinical assessment, but the blinding of clinicians will be 
sufficiently robust to prevent bias in this decision.
secondary outcome measures
Secondary outcome measures include hospital admis-
sion, need for blood transfusion, recurrent epistaxis and 
any thrombotic events requiring any hospital reatten-
dance within 1 week. Any treatment during the index ED 
episode for continued bleeding and further ED hospital 
treatments required for epistaxis during the 7-day 
follow-up period will also be recorded, including details 
of the type of hospital episode.
data collection
Data required for the purposes of the trial will be 
recorded on a study-specific case report form (CRF) by 
the attending clinician, research nurse or other nomi-
nated research team member. To save time during the 
ED attendance, data will be retrospectively recorded in 
the CRF where applicable. At 1-week postattendance, the 
participant will be contacted by a member of the local 
research team to collect follow-up information including 
details of treatment for any further epistaxis and details 
of any other adverse events experienced since discharge.
Postintervention management
Following a maximum of two doses of trial treatment, 
patients will be managed according to local departmental 
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protocols. Any additional treatment(s) will be recorded 
in the CRF. Prior to discharge, all participants will be 
given a more detailed information sheet about the study.
safety monitoring
Extensive evidence supporting the use of both intrave-
nous TXA (CRASH 2)11 and topical TXA10 (Cochrane 
review) in over 30 000 patients supports an excellent 
safety profile, with no reported complications in patients 
receiving topical TXA. The bioavailability of topical TXA 
is unknown (about 50% via GI tract), but the systemic 
absorption of a topical dose of 200 mg (compared with 
standard intravenous dose of 1 g) is extremely unlikely to 
result in significant side effects. The trial design excludes 
patients with haemodynamic instability, where the admin-
istration of trial treatments could delay urgent life-saving 
interventions.
Structured telephone review will allow monitoring of 
all potential complications. Particular attention will be 
paid to the possibility of thrombotic complications as this 
is a recognised side effect of both oral and intravenous 
TXA, although this risk is considered negligible with the 
low-dose topical TXA and the route used in this study.
All serious adverse events (SAEs) will be reported imme-
diately, within 24 hours of discovery, to the CTU who will 
notify the chief investigator. All SAEs will be followed up 
until resolution. Any SAE considered to be related to 
trial treatment and not consistent with the information 
set out in the reference safety information for TXA will 
be classified as a suspected unexpected serious adverse 
reaction and details passed to the sponsor for immediate 
unblinding and expedited reporting to the MHRA, as 
required. In addition to SAEs, non-SAEs considered to be 
possibly, probably or definitely related to trial treatment 
will be recorded.
A summary report of all SAEs and non-SAEs will be 
scrutinised by members of the independent data moni-
toring committee (DMC), trial steering committee (TSC) 
and trial management group on a regular basis.
If an individual suffers negligent harm as a result of 
participating in the trial, NHS indemnity covers NHS staff 
and those people responsible for conducting the trial who 
have honorary contracts with the relevant NHS Trust. In 
the case of non-negligent harm, an ex gratia payment 
may be considered in the event of a claim. There are no 
specific provisions for ancillary or post-trial care.
data handling
Data will be collected and managed in accordance with 
the Data Protection Act 1998/General Data Protection 
Regulation 2018. Each participant will be allocated a 
unique study number and will then be identified in all 
study-related documentation by their identification 
number and initials.
Original CRFs will be posted to the CTU, with copies of 
the CRF retained at the study site. CRFs will be checked 
on receipt at CTU and any obvious errors or omissions 
rectified as far as possible by means of a formalised 
data query/clarification procedure. All data will be 
double entered by CTU staff on to a password-protected 
SQL Server database and encrypted using Secure Sockets 
Layer. Double-entered data will be compared for discrep-
ancies using a stored procedure and discrepant data will 
be verified using the original CRF. After all data cleaning 
duties have been performed and the database locked, 
anonymised data will be exported to the trial statistician 
for blinded analysis.
determination of sample size
The null hypothesis for the trial is that there is no differ-
ence in anterior nasal packing rates for patients with 
persistent epistaxis after first aid and use of a topical vaso-
constrictor, treated with either topical TXA or matched 
placebo. The patients recruited to the study will have 
failed simple first aid measures and vasoconstrictor and 
would ordinarily proceed to packing, according to local 
protocol. It is likely therefore that the need for packing 
in the control arm of the trial will be very high; a small 
number may have their bleeding stopped by the addi-
tional 10 min of dental roll insertion (although soaked in 
placebo), but we expect about 95% to need packing. We 
also expect that TXA might produce a large reduction 
in this need, but given it is inexpensive and safe, even 
a modest reduction would be worthwhile. A reduction 
from 95% to 85%, assuming a corrected χ2 test powered 
at 90% and with a significance level of 5%, requires 207 
patients per group. Because of the nature and timing of 
the primary outcome, we do not envisage much loss to 
follow-up or missing data. To be conservative, we aim to 
recruit a total of 450 patients.
statistical analysis
A statistical analysis plan will be prepared by the trial 
statistician and approved by the DMC in advance of any 
analysis. The trial statistician will conduct the statistical 
analysis by nominal group (ie, blinded to treatment 
allocation) and present the results for interpretation 
by blinded members of the trial team and oversight 
committee, prior to disclosure of the treatment allocation 
and further interpretation of the study findings. There 
are no preplanned interim analyses.
Consolidated Standards of Reporting Trials guide-
lines18 will be used to present descriptive data on patients 
screened, recruited, randomised and treated, and any 
lost to follow-up. Descriptive data will be presented on 
baseline characteristics, for example, demographics. All 
primary comparative analyses will be based on the inten-
tion-to-treat principle, with consideration given to addi-
tional sensitivity analyses as appropriate considering per 
protocol populations (if different) and imputation for 
missing data. The outcomes (including, in particular, the 
primary outcome) are binary in nature and will be anal-
ysed by mixed effects logistic regression with centre as a 
random effect. All comparative analyses will be reported 
with point estimates (ORs), 95% CIs and p values.
7Reuben A, et al. BMJ Open 2019;9:e026882. doi:10.1136/bmjopen-2018-026882
Open access
Missing data
Given the nature of the short follow-up and a limited 
amount of data to be collected, it is not anticipated 
that there will be many missing data. Every attempt will 
be made to retrieve any missing data. Where there data 
remain missing, sensitivity analyses may be conducted 
using a range of assumptions where necessary and consid-
eration given to suitable imputation.
study management and oversight
The study sponsor organisation is the RD&E NHS Foun-
dation Trust, Barrack Road, Exeter EX2 5DW. Day-to-day 
trial management is administered through the UKCRC 
(clinical research collaboration)-registered Peninsula 
CTU at Plymouth University. A trial management group 
including the chief investigator, CTU trial managers, trial 
statistician and other personnel relevant to the study (eg, 
clinicians, clinical trials pharmacist, CTU data manager, 
patient and sponsor representatives) will meet regularly 
(usually monthly) throughout the duration of the trial to 
oversee practical management of the trial.
A TSC, chaired by an independent member, will 
oversee the conduct and safety of the trial, ensuring that 
milestones are achieved and general scientific probity is 
maintained. An independent DMC will monitor the safety 
and ethics of the trial by overseeing recruitment, primary 
outcome data completeness and accumulating safety data.
Patient and public involvement
A patient advisory group was established to contribute to 
the design of the study from the outset, including input 
into the proposed trial interventions. This group was 
made of individuals with prior experience of epistaxis 
requiring hospital treatment. Further to this, public 
involvement is maintained through patient representa-
tion on the trial management group and TSC. Results will 
be disseminated to study participants via a website hosted 
by the CTU and to a wider patient group via Hereditary 
Haemorrhagic Telangiectasia (CureHHT).
Ethics and dissemination
The trial complies with the Declaration of Helsinki and 
GCP guidelines. All eligible, willing participants will 
undergo full written informed consent by GCP-trained 
staff before taking any part in the study. All protocol 
modifications will be reviewed by the study sponsor and 
communicated to relevant parties once approved.
The results will be applicable and of interest to emer-
gency physicians, paramedics, acute physicians, NHS Trusts, 
general practitioners, emergency care practitioners and 
patients and efforts will be made to disseminate the infor-
mation to all of these groups. To that end, the study will 
be submitted for publication in international, high impact, 
peer-reviewed journals whose target audience includes 
appropriate clinicians. Results will also be shared with the 
HHT foundation and telangiectasia UK (patient groups at 
significant risk of epistaxis) for publication on their websites 
and presentation through appropriate related forums. After 
the end of the study, information collected during the study 
may be made available as an anonymised participant-level 
dataset to other researchers under an appropriate data 
sharing agreement.
dIsCussIon
The Nasal Packing in Epistaxis study is a multicentre 
RCT designed to investigate the value of topical intra-
nasal TXA for patients presenting to an ED with epistaxis 
that persists after simple first aid measures. Such patients 
frequently progress to requiring anterior nasal packing. 
While effective, packing is not a benign procedure, can 
be extremely painful, invariably requires hospital admis-
sion and has side effects and potential significant compli-
cations. TXA is safe, cheap and readily available.
A pragmatic design is intended to enhance, rather 
than impede, the patient journey. The study protocol 
follows an SOP for the management of epistaxis, which 
all recruiting centres have adopted in advance of the 
trial opening. Given the unpredictable, busy and chal-
lenging nature of the ED environment, all appropriate 
steps have been taken to ensure that the trial processes 
are simple and straightforward to complete. The trial 
has been specifically designed to meet its objectives and 
recruitment targets in this challenging ED setting, using 
a carefully considered effect size and accrual rate based 
on data from participating sites. The trial interventions 
will not interfere with the standard ED management of 
epistaxis, so patients will not in anyway be disadvantaged 
by their inclusion.
If TXA was found to be a useful adjunct to the manage-
ment of persistent epistaxis, it could obviate the need for 
nasal packing in those patients where it is effective and 
reduce the need for hospital admission. This would be an 
important finding for the benefit of patients and health-
care systems.
Anterior nasal packing is an effective, but an uncom-
fortable method for controlling persistent epistaxis 
that usually requires hospital admission. Topical TXA 
has been shown to be safe and effective in a number of 
settings and there is some evidence that it may be of value 
in selected patients with epistaxis, although the question 
is yet to be fully evaluated. The results of this study could 
realistically lead to a reduction in the need for anterior 
nasal packing and thus hospital admission for patients 
with epistaxis and the reduction in for an uncomfortable 
procedure with recognised complications.
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